4-氯-7-碘-喹啉-3-甲腈 | 364793-64-6

• 物质功能分类: 医药中间体 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-氯-7-碘-喹啉-3-甲腈
• 英文名称: 4-chloro-7-iodo-3-quinolinecarbonitrile
• 英文别名: 4-Chloro-7-iodoquinoline-3-carbonitrile
• CAS: 364793-64-6
• 化学式: C₁₀H₄ClIN₂
• 分子量: 314.513
• InChiKey: YZEWSNLPWKBALG-UHFFFAOYSA-N

物化性质

• 沸点：
  423.3±40.0 °C(Predicted)
• 密度：
  1.99±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-氯-7-碘-喹啉-3-甲腈 在 bis-triphenylphosphine-palladium(II) chloride 、 吡啶盐酸盐 作用下， 以 1,4-二氧六环 、 乙二醇乙醚 为溶剂， 生成 4-(2,4-dichloro-5-methoxyanilino)-7-[5-(1,3-dioxolan-2-yl)-thien-2-yl]-3-quinolinecarbonitrile
  参考文献：
  名称：

  Inhibition of Src kinase activity by 4-anilino-7-thienyl-3-quinolinecarbonitriles

  摘要：

  Based on a screening lead from a yeast-based assay to identify Src family kinase inhibitors, a series of 4-anilino-7-thienyl-3-quinolinecarbonitriles was prepared. When the thiophene ring was substituted with a water-solubilizing group in a 2,5-, 3,5- or 2,4-pattern, potent inhibition of Src kinase activity was observed. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00302-5
• 作为产物：
  描述：

  1,4-二氢-7-碘-4-氧代-3-喹啉甲腈 在 三氯氧磷 作用下， 生成 4-氯-7-碘-喹啉-3-甲腈
  参考文献：
  名称：

  Inhibition of Src kinase activity by 4-anilino-7-thienyl-3-quinolinecarbonitriles

  摘要：

  Based on a screening lead from a yeast-based assay to identify Src family kinase inhibitors, a series of 4-anilino-7-thienyl-3-quinolinecarbonitriles was prepared. When the thiophene ring was substituted with a water-solubilizing group in a 2,5-, 3,5- or 2,4-pattern, potent inhibition of Src kinase activity was observed. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00302-5

文献信息

• 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
  申请人：American Home Products Corporation

  公开号：US20020026052A1

  公开（公告）日：2002-02-28

  This invention provides compounds of Formula (I), having the structure 1 where T, Z, X, A, R 1 , R 2a , R 2b , R 2c , R 3 , R 4 , and n are defined herein, or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of osteoporosis and polycystic kidney disease.

  这项发明提供了具有结构的化合物（I）的公式， 其中T、Z、X、A、R 1 、R 2a 、R 2b 、R 2c 、R 3 、R 4 和n在此处定义，或其药学上可接受的盐，这些化合物可用作抗肿瘤药物，并用于骨质疏松症和多囊肾病的治疗。
• Design and Analysis of the 4‐Anilinoquin(az)oline Kinase Inhibition Profiles of GAK/SLK/STK10 Using Quantitative Structure‐Activity Relationships
  作者：Christopher R. M. Asquith、Tuomo Laitinen、James M. Bennett、Carrow I. Wells、Jonathan M. Elkins、William J. Zuercher、Graham J. Tizzard、Antti Poso

  DOI：10.1002/cmdc.201900521

  日期：2020.1.7

  have been associated with negative clinical outcomes. We have designed and synthesized a series of 4-anilinoquin(az)olines in order to better understand the structure-activity relationships of three main collateral kinase targets of quin(az)oline-based kinase inhibitors: cyclin G associated kinase (GAK), STE20-like serine/threonine-protein kinase (SLK) and serine/threonine-protein kinase 10 (STK10)

  4-苯胺基喹啉和4-苯胺基喹唑啉环系统一直是现有激酶药物发现计划中的重大工作重点，这些计划已开发出获批的药物。随着先进的筛选技术的出现，现在已经评估了这些化合物的广泛的动力学特征。这些环系统最初是为包括表皮生长因子受体（EGFR）在内的特定靶标设计的，但实际上显示了许多有效的附带激酶靶标，其中一些与阴性临床结局有关。我们设计和合成了一系列4-苯胺基喹啉（az）脯氨酸，以便更好地了解基于喹（唑啉的激酶抑制剂的三个主要附带激酶靶的结构-活性关系：细胞周期蛋白G相关激酶（GAK），STE20样丝氨酸/苏氨酸蛋白激酶（SLK）和丝氨酸/苏氨酸蛋白激酶10（STK10）。这是通过一系列定量构效关系（QSAR）分析，激酶ATP结合位点的水位分析以及广泛的小分子X射线结构分析实现的。
• [EN] 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS<br/>[FR] 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES ET 3-CYANO-1,7-NAPHTHYRIDINES UTILISEES COMME INHIBITEURS DE PROTEINEKINASE
  申请人：AMERICAN HOME PROD

  公开号：WO2001072711A1

  公开（公告）日：2001-10-04

  Compounds of Formula (I), having the structure or a pharmaceutically salt thereof are useful as antineoplastic agents and in the treatment of osteoporosis and polycystic kidney disease.

  具有结构式（I）或其药物盐的化合物在抗肿瘤药物和治疗骨质疏松症和多囊肾病方面是有用的。
• Potent antiviral activity of novel multi-substituted 4-anilinoquin(az)olines
  作者：Sirle Saul、Szu-Yuan Pu、William J. Zuercher、Shirit Einav、Christopher R.M. Asquith

  DOI：10.1016/j.bmcl.2020.127284

  日期：2020.8

  Screening a series of 4-anilinoquinolines and 4-anilinoquinazolines enabled identification of potent novel inhibitors of dengue virus (DENV). Preparation of focused 4-anilinoquinoline/quinazoline scaffold arrays led to the identification of a series of high potency 6-substituted bromine and iodine derivatives. The most potent compound 6-iodo-4-((3,4,5-trimethoxyphenyl)amino)quinoline-3-carbonitrile (47) inhibited DENV infection with an EC50 = 79 nM. Crucially, these compounds showed very limited toxicity with CC(50 )values > 10 mu M in almost all cases. This new promising series provides an anchor point for further development to optimize compound properties.
• Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors
  作者：Albert W. Garofalo、Marc Adler、Danielle L. Aubele、Elizabeth F. Brigham、David Chian、Maurizio Franzini、Erich Goldbach、Grace T. Kwong、Ruth Motter、Gary D. Probst、Kevin P. Quinn、Lany Ruslim、Hing L. Sham、Danny Tam、Pearl Tanaka、Anh P. Truong、Xiaocong M. Ye、Zhao Ren

  DOI：10.1016/j.bmcl.2013.02.041

  日期：2013.4

  Mutations in leucine-rich repeat kinase 2 (LRRK2) are associated with familial Parkinson's disease (PD). The kinase activity of this complex protein is increased by pathogenic mutations. Inhibition of LRRK2 kinase activity has therefore emerged as a promising approach for the treatment of PD. Herein we report our findings on a series of 4-alkylamino-7-aryl-3-cyanoquinolines that exhibit kinase inhibitory activity against both wild type and G2019S mutant LRRK2. Activity was determined in both biochemical and cellular assays. Compound 14 was further evaluated in an in vivo pharmacodynamic study and found to significantly inhibit Ser935 phosphorylation after oral dosing. (C) 2013 Elsevier Ltd. All rights reserved.